News
NAMS
20.18
+1.05%
0.21
NewAmsterdam Pharma Is Maintained at Overweight by Cantor Fitzgerald
Dow Jones · 2d ago
NewAmsterdam Pharma price target raised to $61 from $52 at Cantor Fitzgerald
TipRanks · 2d ago
Cantor Fitzgerald Maintains Overweight on NewAmsterdam Pharma Co, Raises Price Target to $61
Benzinga · 2d ago
Analysts’ Top Healthcare Picks: Edwards Lifesciences (EW), Helus Pharma (HELP)
TipRanks · 4d ago
Piper Sandler Sticks to Their Buy Rating for NewAmsterdam Pharma Company (NAMS)
TipRanks · 4d ago
Weekly Report: what happened at NAMS last week (1102-1106)?
Weekly Report · 4d ago
NewAmsterdam’s European Approvals and Pipeline Progress Support Buy Rating; $52 Price Target Unchanged
TipRanks · 11/06 13:58
NewAmsterdam Pharma Is Maintained at Buy by Needham
Dow Jones · 11/05 21:43
NewAmsterdam Pharma Price Target Cut to $46.00/Share From $48.00 by Needham
Dow Jones · 11/05 21:43
Needham Maintains Buy on NewAmsterdam Pharma Co, Lowers Price Target to $46
Benzinga · 11/05 21:33
NewAmsterdam Pharma Company (NAMS) Gets a Buy from Leerink Partners
TipRanks · 11/05 14:29
BMO Capital Reaffirms Their Buy Rating on NewAmsterdam Pharma Company (NAMS)
TipRanks · 11/05 13:28
NewAmsterdam Pharma GAAP EPS of -$0.14 beats by $0.30, revenue of $19.16M beats by $4.11M
Seeking Alpha · 11/05 05:30
NewAmsterdam Pharma Company N.V. Reports Third Quarter Financial Results and European Commission Approval
NASDAQ · 11/04 18:41
NewAmsterdam Pharma reports Q3 EPS (14c), consensus (44c)
TipRanks · 11/04 13:23
Weekly Report: what happened at NAMS last week (1026-1030)?
Weekly Report · 11/02 10:07
Weekly Report: what happened at NAMS last week (1019-1023)?
Weekly Report · 10/26 10:07
Weekly Report: what happened at NAMS last week (1012-1016)?
Weekly Report · 10/19 10:07
Citi Sticks to Their Buy Rating for NewAmsterdam Pharma Company (NAMS)
TipRanks · 10/15 11:45
Seeking Alpha’s Quant Spotlight: Highest and lowest rated healthcare stocks ahead of Q3
Seeking Alpha · 10/13 13:35
More
Webull provides a variety of real-time NAMS stock news. You can receive the latest news about NewAmsterdam Pharma Company N.V through multiple platforms. This information may help you make smarter investment decisions.
About NAMS
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.